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a b s t r a c t
Antithrombin (AT) deficiency is a rare autosomal dominant disorder which increases the
risk of venous thromboembolism (VTE). We report here the case of type II antithrombin
deficiency in 44-year-old man who developed left leg deep vein thrombosis (DVT). All
exons of SERPINC1, the gene encoding AT were amplified by PCR followed by direct
sequencing. A heterozygous mutation c.166C>T in exon 2 causing the amino acid substi-
tution of Arg to Cys at residue 56, was found. This mutation does not affect the folding
and secretion of the protein, but impairs the heparin affinity, reducing the anticoagulant
activity of AT.
To the best of our knowledge, this is a first report of AT type IIHBS deficiency related
to Polish patient who experienced DVT.
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Antithrombin (AT) is a 58 kDa glycoprotein synthesized in
the liver, which belongs to the serine protease inhibitors
superfamily (serpins) and play a key role as a natural blood
anticoagulant. AT forms inactive complex with thrombin
and activated factor Xa that prevents blood clotting. Pre-
sence of heparin increases this activity 1000-fold [1].
The human gene encoding AT (SERPINC1) is located on
the chromosome 1q23-25 and consists of 7 exons and
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z o.o. All rights reserved.deficiency have been reported [3]. More than half of these
genetic disorders are missense mutations, which lead to
dysfunctional proteins. The others like insertions, deletions
and nonsense mutations, typically cause disruption or
absence of gene product [4]. Hitherto, there were identified
14 different mutations corresponding to AT deficiency
among the Polish patients [5].
Inherited AT deficiency is an autosomal dominant dis-
order that concerns between 1:600 and 1:5000 of total popula-
tion [6]. There are two types of inherited AT deficiency, both
are associated with reduced AT activity but only type I is
related to lower AT antigen levels in blood. Type II can beki Collegium Medicum, ul. Prądnicka 80, 31-202 Kraków, Poland.
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mutations: type IIRS is characterized by reactive site defects,
type IIHBS is associated with heparin-binding site and type
IIPE is caused by mutations clustered in the C-terminus
region of AT protein [7]. AT deficiency increases 20-fold the
risk of venous thromboembolism (VTE) [8].
We report here the first Polish case of AT type IIHBS
deficiency caused by heterozygous point mutation c.166C>T,
p.Arg56Cys (Human Genome Variation Society numbering
system) in second exon of SERPINC1 gene.
Case report
A 45-year-old overweight male patient 5 months after
idiopathic left-sided deep vein thrombosis (DVT) was
referred for thrombophilia screening. Six months before the
incident he suffered a left tibia injury but without the need
of plaster. Venous duplex ultrasound scans showed popli-
teal and superficial femoral veins reflux and thrombi within
the tibial veins.
After a trauma the patient was treated with rivaroxaban
(Xarelto) 20 mg/d and this therapy is still continued. No
signs of bleeding or DVT recurrence were observed during
12 months of therapy.
The proband was the only child. Family history revealed
lower limb varices without documented VTE in his mother.
The proband's father died of myocardial infarction (MI)
before the age of 60. A 16-year proband's son remained
asymptomatic.
The most common thrombophilic factors, including Fac-
tor V Leiden and prothrombin G20210A mutations, were
absent. Plasma protein C, free protein S, antiphospholipid
antibodies, factor FVIII and homocysteine were within
normal limits. Lupus anticoagulant was negative.
Antithrombin anti-FX activity, measured by two different
chromogenic assays: (Berichrom AT, Siemens, Marburg,
Germany, reference range 75–125%, and HemosIL, Instru-
mentation Laboratory SpA, Milano, Italy, reference range
80–120%), were 56% and 49%, respectively. AT antigen levels
were performed using a home-made sandwich ELISA kit
(reference range 80–120%) and was 98%.
Moreover, plasma AT was evaluated by electrophoretic
analysis using sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) performed in 8% polyacryamide
gel and native PAGE with the presence and absence of 6 M
urea as described previously [9]. After separation, proteins
were transblotted onto polyvinylidene fluoride (PVDF) mem-
brane. AT was immunostained with rabbit anti-human AT
polyclonal antibody (Sigma, Madrid, Spain) and followed by
donkey anti-rabbit IgG horseradish peroxidase (HRP) conju-
gate (GE Healthcare, Barcelona, Spain) with detection by ECL
kit (Amersham Bioscences, Piscataway, NJ). Analyses did not
identify any abnormal bands that might correspond to
variant AT, except native gels, which shows two bands, one
with faster electrophoretic mobility and similar intensity to
the wild type, which is typical of mutations affecting
arginine residues at the heparin binding domain.
After obtained informed written consent, the blood
sample was collected in EDTA for DNA analysis. The 7 exonsand flanking regions of SERPINC1 gene were amplified using
polymerase chain reaction (PCR) followed by direct DNA
sequencing. A heterozygous point mutation c.166C>T that
causes a missense protein sequence change p.Arg56Cys
(number considering the whole protein) in exon 2 was found.
In addition, protein in silico analysis using PoliPhen-2
and Sorting Intolerant From Tolerant (SIFT) were performed.
The obtained result classifies this mutation as ‘probably
damaging’ with score 0.999.
Discussion
To the best of our knowledge, this is a first report of AT type
II HBS deficiency detected in a Polish patient who experi-
enced DVT.
The mutation identified in this patient was previously
described by Perry and Carrell in 1989 in a 25-year-old man
who developed an unexpected coronary thrombosis. This
report demonstrated that the described mutation caused
a variant known as ‘Antithrombin Rouen IV’ [10]. It has been
also reported by Luxembourg et al. that 1 out of 272 patients
with reduced values of AT activity/AT antigen and throm-
boembolic event, and with positive family history for DVT,
carried the p.Arg56Cys variant [11]. However, a recent cohort
study shows that the carriers of IIHBS AT deficiency have
a 80% lower risk of VTE and 6-fold higher risk of arterial
thromboembolism than carriers of other type of AT defi-
ciency [4]. These mutations are usually combined with other
thrombotic risk factors in patients with VTE [12]. We show
here uncommon clinical presentation of Antithrombin
Rouen IV since our patient developed DVT without addi-
tional risk factors.
Antithrombin Rouen IV occurs at CpG dinucleotides
(CpGs) which are the hotspots for point mutations in
SERPINC1 gene [10]. The cytosine (C) residue in the CpG
region is methylated and the product of this process (5-
methylocytosine) may be spontaneously deaminated form-
ing thymine (T). This change is not enzymatic repaired and
results in a C to T transition on one DNA strand and
consequently, change G to A on a opposite DNA strand.
It has been shown that the CpGs mutations are mainly
involved in the development of AT type IIHBS deficiency in
opposition to type IIRS and IIPE [10, 13].
Arginine at residue 56 is located in N-terminal sequence
and is involved in protein conformational changes induced
by binding of heparin [11]. Replacement of this amino acid
by cysteine has the influence on decreased heparin affinity.
It is important to point out that certain functional methods
for measuring AT activity in the presence of heparin fail to
detect this mutation [14].
In conclusion, our report supports the need for thrombo-
philia screening in VTE patients below 50 years of age,
especially in the absence of the established risk factors.
Similar strategy should be considered in arterial thrombosis
at young age as evidenced for instance in our report on
protein C deficiency detected after MI in a young man [15].
Appropriate and timely anticoagulation in symptomatic
patients with inherited AT deficiency can reduce the risk of
recurrent thrombotic events. Life-long anticoagulant treat-
a c t a h a e m a t o l o g i c a p o l o n i c a 4 6 ( 2 0 1 5 ) 3 9 3 – 3 9 5 395ment should be considered in AT deficient patients if they
experienced a first-ever idiopathic VTE episode as well as
those with two episodes. Prophylactic anticoagulation in
asymptomatic carriers, especially if family history for VTE
is present may be used in certain high-risk state such as
pregnancy or surgery.
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